Cargando…
Design and Optimization of In Situ Gelling Mucoadhesive Eye Drops Containing Dexamethasone
Poor bioavailability of eye drops is a well-known issue, which can be improved by increasing the residence time on the eye surface and the penetration of the active pharmaceutical ingredient (API). This study aims to formulate in situ gelling mucoadhesive ophthalmic preparations. To increase the res...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9498616/ https://www.ncbi.nlm.nih.gov/pubmed/36135271 http://dx.doi.org/10.3390/gels8090561 |
_version_ | 1784794804415102976 |
---|---|
author | Szalai, Boglárka Jójárt-Laczkovich, Orsolya Kovács, Anita Berkó, Szilvia Balogh, György Tibor Katona, Gábor Budai-Szűcs, Mária |
author_facet | Szalai, Boglárka Jójárt-Laczkovich, Orsolya Kovács, Anita Berkó, Szilvia Balogh, György Tibor Katona, Gábor Budai-Szűcs, Mária |
author_sort | Szalai, Boglárka |
collection | PubMed |
description | Poor bioavailability of eye drops is a well-known issue, which can be improved by increasing the residence time on the eye surface and the penetration of the active pharmaceutical ingredient (API). This study aims to formulate in situ gelling mucoadhesive ophthalmic preparations. To increase the residence time, the formulations were based on a thermosensitive polymer (Poloxamer 407 (P407)) and were combined with two types of mucoadhesive polymers. Dexamethasone (DXM) was solubilized by complexation with cyclodextrins (CD). The effect of the composition on the gel structure, mucoadhesion, dissolution, and permeability was investigated with 3(3) full factorial design. These parameters of the gels were measured by rheological studies, tensile test, dialysis membrane diffusion, and in vitro permeability assay. The dissolution and permeability of the gels were also compared with DXM suspension and CD-DXM solution. The gelation is strongly determined by P407; however, the mucoadhesive polymers also influenced it. Mucoadhesion increased with the polymer concentration. The first phase of drug release was similar to that of the CD-DXM solution, then it became prolonged. The permeability of DXM was significantly improved. The factorial design helped to identify the most important factors, thereby facilitating the formulation of a suitable carrier for the CD-DXM complex. |
format | Online Article Text |
id | pubmed-9498616 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94986162022-09-23 Design and Optimization of In Situ Gelling Mucoadhesive Eye Drops Containing Dexamethasone Szalai, Boglárka Jójárt-Laczkovich, Orsolya Kovács, Anita Berkó, Szilvia Balogh, György Tibor Katona, Gábor Budai-Szűcs, Mária Gels Article Poor bioavailability of eye drops is a well-known issue, which can be improved by increasing the residence time on the eye surface and the penetration of the active pharmaceutical ingredient (API). This study aims to formulate in situ gelling mucoadhesive ophthalmic preparations. To increase the residence time, the formulations were based on a thermosensitive polymer (Poloxamer 407 (P407)) and were combined with two types of mucoadhesive polymers. Dexamethasone (DXM) was solubilized by complexation with cyclodextrins (CD). The effect of the composition on the gel structure, mucoadhesion, dissolution, and permeability was investigated with 3(3) full factorial design. These parameters of the gels were measured by rheological studies, tensile test, dialysis membrane diffusion, and in vitro permeability assay. The dissolution and permeability of the gels were also compared with DXM suspension and CD-DXM solution. The gelation is strongly determined by P407; however, the mucoadhesive polymers also influenced it. Mucoadhesion increased with the polymer concentration. The first phase of drug release was similar to that of the CD-DXM solution, then it became prolonged. The permeability of DXM was significantly improved. The factorial design helped to identify the most important factors, thereby facilitating the formulation of a suitable carrier for the CD-DXM complex. MDPI 2022-09-02 /pmc/articles/PMC9498616/ /pubmed/36135271 http://dx.doi.org/10.3390/gels8090561 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Szalai, Boglárka Jójárt-Laczkovich, Orsolya Kovács, Anita Berkó, Szilvia Balogh, György Tibor Katona, Gábor Budai-Szűcs, Mária Design and Optimization of In Situ Gelling Mucoadhesive Eye Drops Containing Dexamethasone |
title | Design and Optimization of In Situ Gelling Mucoadhesive Eye Drops Containing Dexamethasone |
title_full | Design and Optimization of In Situ Gelling Mucoadhesive Eye Drops Containing Dexamethasone |
title_fullStr | Design and Optimization of In Situ Gelling Mucoadhesive Eye Drops Containing Dexamethasone |
title_full_unstemmed | Design and Optimization of In Situ Gelling Mucoadhesive Eye Drops Containing Dexamethasone |
title_short | Design and Optimization of In Situ Gelling Mucoadhesive Eye Drops Containing Dexamethasone |
title_sort | design and optimization of in situ gelling mucoadhesive eye drops containing dexamethasone |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9498616/ https://www.ncbi.nlm.nih.gov/pubmed/36135271 http://dx.doi.org/10.3390/gels8090561 |
work_keys_str_mv | AT szalaiboglarka designandoptimizationofinsitugellingmucoadhesiveeyedropscontainingdexamethasone AT jojartlaczkovichorsolya designandoptimizationofinsitugellingmucoadhesiveeyedropscontainingdexamethasone AT kovacsanita designandoptimizationofinsitugellingmucoadhesiveeyedropscontainingdexamethasone AT berkoszilvia designandoptimizationofinsitugellingmucoadhesiveeyedropscontainingdexamethasone AT baloghgyorgytibor designandoptimizationofinsitugellingmucoadhesiveeyedropscontainingdexamethasone AT katonagabor designandoptimizationofinsitugellingmucoadhesiveeyedropscontainingdexamethasone AT budaiszucsmaria designandoptimizationofinsitugellingmucoadhesiveeyedropscontainingdexamethasone |